Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Peptides like BPC-157 are flooding gyms, social media, and now doctors' offices — but orthopedic surgeons say the science hasn't caught up with the buzz. Despite a new HHS draft policy expanding compounding pharmacy access, clinical evidence in humans remains nearly nonexistent. Experts urge caution around purity, safety, and anti-doping risks while calling for proper clinical trials.
Peptides — short chains of amino acids marketed for injury healing, athletic recovery, and longevity — are showing up in orthopedic clinics at a rapid pace, driven by social media influencers, biohackers, and wellness clinics. On Oct. 28, 2026, HHS Secretary RFK Jr. released a draft enforcement policy allowing compounding pharmacies to prepare certain peptides, including BPC-157, without fear of enforcement action — a move that could significantly widen patient access before formal FDA rulemaking is complete.
But orthopedic surgeons are pumping the brakes. While preclinical and animal studies show promising signals — including enhanced angiogenesis, reduced inflammatory cytokines, and improved tissue repair — virtually no human clinical data exists to confirm these benefits. A 2025 systematic review found 35 of 36 studies on BPC-157 were preclinical, with the sole clinical study lacking safety data. Concerns also extend to product purity: synthetic peptides sold online are largely unregulated, and a federal criminal case involving Paradigm Peptides revealed falsified lab testing documents.
Key Takeaways:
Why it matters: With patients asking about peptides multiple times per clinic day, orthopedic surgeons need to be fluent in the terminology and risks — even if they're not prescribing them. The gap between patient enthusiasm and clinical evidence is wide, and closing it will require rigorous trials that the industry currently has little incentive to fund.
